SPHK2 and diabetes mellitus: A further gene of interest among the top 100 intrinsically sex-differently expressed podocyte genes that showed sex-different responses to rapamycin is Sphk2. Sphk2 has been shown to be involved in kidney fibrosis and diabetes-induced podocytopathy and has recently been suggested as pharmaceutical target to treat proteinuric kidney disease [123, 124].